- Home
- TMDX
as 12-18-2024 11:43am EST
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | ANDOVER |
| Market Cap: | 2.7B | IPO Year: | 2019 |
| Target Price: | $116.10 | AVG Volume (30 days): | 1.9M |
| Analyst Decision: | Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.94 | EPS Growth: | N/A |
| 52 Week Low/High: | $60.80 - $177.37 | Next Earning Date: | 10-28-2024 |
| Revenue: | $401,090,000 | Revenue Growth: | 109.09% |
| Revenue Growth (this year): | 82.52% | Revenue Growth (next year): | 25.91% |
Stock Insider Trading Activity of TransMedics Group Inc. (TMDX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Khayal Tamer I | TMDX | Chief Commercial Officer | Dec 2 '24 | Sell | $86.40 | 1,084 | $93,657.60 | 20,843 | |
| Khayal Tamer I | TMDX | Chief Commercial Officer | Nov 11 '24 | Sell | $90.04 | 1,458 | $131,278.32 | 20,843 | |
| Basile Edward M | TMDX | Director | Nov 5 '24 | Sell | $83.82 | 6,750 | $563,993.80 | 2,186 | |
| Khayal Tamer I | TMDX | Chief Commercial Officer | Nov 1 '24 | Sell | $82.64 | 1,083 | $89,499.12 | 20,843 | |
| Hassanein Waleed H | TMDX | President & CEO | Oct 15 '24 | Sell | $133.50 | 8,625 | $1,144,648.13 | 66,661 | |
| Khayal Tamer I | TMDX | Chief Commercial Officer | Oct 1 '24 | Sell | $150.34 | 2,958 | $438,490.90 | 20,843 |
Latest TransMedics Group Inc. News
TMDX Breaking Stock News: Dive into TMDX Ticker-Specific Updates for Smart Investing
MT Newswires
a day ago
JPMorgan Downgrades TransMedics Group to Neutral From Overweight, Cuts Price Target to $75 From $116
Zacks
5 days ago
TransMedics Stock Plunges 57.5% in Three Months: What's Next?
PR Newswire
6 days ago
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Motley Fool
7 days ago
2 Healthcare Stocks to Buy Hand Over Fist and 1 to Avoid
Argus Research
8 days ago
TMDX: Lowering target price to $55.00
Insider Monkey
9 days ago
TransMedics Group, Inc. (TMDX): A Bull Case Theory
Motley Fool
10 days ago
Down Over 60%, Is TransMedics Stock a Buy on the Dip?
Motley Fool
12 days ago
Why Transmedics Group Stock Plummeted 21% This Week
Compare TMDX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TMDX TransMedics Group Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.